Valuation: IO Biotech, Inc.

Market Cap 43.81M 38.14M 36M 32.71M 61.28M 4.2B 61.56M 431M 166M 2.14B 165M 161M 6.87B P/E 2023
-0.95x
P/E 2024 -0.63x
Enterprise Value -14.31M -12.46M -11.76M -10.68M -20.01M -1.37B -20.1M -141M -54.31M -698M -53.74M -52.54M -2.24B EV / Sales 2023
-
EV / Sales 2024 -
Free-Float
99.69%
Yield 2023 *
-
Yield 2024 -
1 day-50.00%
1 week+9,900.00%
Current month+9,900.00%
3 months-98.33%
6 months-99.95%
Current year-99.98%
1 week 0
Extreme 0.0001
0
1 month 0
Extreme 1.0E-6
0
Current year 0
Extreme 1.0E-6
0.7
1 year 0
Extreme 1.0E-6
1.67
3 years 0
Extreme 1.0E-6
2.79
5 years 0
Extreme 1.0E-6
17.88
10 years 0
Extreme 1.0E-6
17.88
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer - 2021-09-30
Compliance Officer 58 2023-01-22
Investor Relations Contact - 2023-03-31
Date Insider Type Main position Quantity % Market Cap. Importance
6/5/25 Free

Director

35,144 0.0533%
6/5/25 Free

Director

35,144 0.0533%
6/5/25 Free

Director

35,144 0.0533%
Change 5-day change 1-year change 3-year change Capi.($)
-50.00%+9,900.00%-99.99%-99.99% 7.19K
+0.11%+2.71%+0.33%+28.59% 46.28B
-1.12%+1.78%+42.30%+27.55% 43.85B
-3.04%-6.29%+338.56%+515.97% 40.93B
-0.74%+1.25%+4.92%+67.98% 39.9B
-0.50%+0.67%+11.79%+40.51% 29.5B
-0.46%+4.22%+22.81%+139.44% 17.09B
-0.97%-10.17% - - 15.55B
-0.57%+8.12%+22.19%+38.68% 15.22B
-3.14%+31.91%-11.79% - 14.05B
Average -6.04%+3.39%+36.79%+94.84% 26.24B
Weighted average by Cap. -1.10%+1.87%+68.20%+131.15%

Financials

2023 2024
Net sales - -
Net income -86.08M -74.95M -70.74M -64.27M -120M -8.25B -121M -846M -327M -4.2B -323M -316M -13.5B -95.49M -83.14M -78.48M -71.3M -134M -9.16B -134M -939M -363M -4.66B -359M -351M -14.98B
Net Debt -141M -122M -116M -105M -197M -13.49B -198M -1.38B -534M -6.86B -528M -517M -22.07B -58.12M -50.6M -47.76M -43.39M -81.29M -5.57B -81.66M -571M -221M -2.83B -218M -213M -9.12B
Logo IO Biotech, Inc.
IO Biotech Inc is a clinical-stage biopharmaceutical company developing immune-modulating cancer therapies based on T-win technology platform. The Company’s product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression. IO Biotech’s lead product candidate, IO102-IO103, is designed to target the immunosuppressive mechanisms mediated by key immunosuppressive proteins such as IDO and PD-L1. The Company develops a pipeline of product candidates that leverage its T-win technology platform to address targets within the TME. The Company is spin-off of National Cancer for Center Immune Therapy at Herlev University Hospital in Denmark.
Employees
80
Date Price Change Volume
26-09-18 US$0.000100 -50.00% 4,154
26-09-17 US$0.000200 +100.00% 66,698
26-09-16 US$0.000100 0.00% 30,551
26-09-15 US$0.000100 0.00% 5,042

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IOBTQ Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!